Drug Trial Radar · NCT04187144
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,606
Actual
Start
Apr 23, 2020
Primary completion
Dec 1, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.
Conditions
- Urinary Tract Infections
Interventions
GepotidacinDrug
Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
Placebo matching nitrofurantoinDrug
Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
NitrofurantoinDrug
Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
Placebo matching gepotidacinDrug
Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)Time frame: TOC visit (Days 9 to 16)
- Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S PopulationTime frame: TOC visit (Days 9 to 16)
Locations
113 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Homewood, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Gilbert, Arizona
GSK Investigational Site
Peoria, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Valencia, California
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Apollo Beach, Florida
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Coconut Creek, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Leesburg, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Ormond Beach, Florida
GSK Investigational Site
Palm Springs, Florida
GSK Investigational Site
Pembroke Pines, Florida
GSK Investigational Site
Plant City, Florida
GSK Investigational Site
Sweetwater, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Blackfoot, Idaho
GSK Investigational Site
Boise, Idaho
GSK Investigational Site
Meridian, Idaho
GSK Investigational Site
Hanover, Maryland
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Butte, Montana
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
East Orange, New Jersey
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.